John Evans, Beam Therapeutics CEO

Beam re­veals what tripped up its base-edit­ed, off-the-shelf CAR-T as it tries to clear FDA hold

Last month, Beam Ther­a­peu­tics re­vealed the FDA in­tend­ed to place its pre­clin­i­cal off-the-shelf CAR-T ther­a­py on hold. To­day, the com­pa­ny re­vealed the rea­sons why. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.